NEW YORK and CAESAREA, Israel, Aug.
15, 2019 /PRNewswire/ -- DarioHealth Corp.
("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global
digital therapeutics company, today announced an alliance with
DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor
Health Initiative (the "Initiative"), which aims to partner leading
Israeli digital health companies with the UK National Health
Service (NHS) to benefit patients.
Dario was selected by DH.L to help bring its highly regarded
digital therapeutics technology to assist NHS patients in better
managing their chronic health conditions, such as pre-diabetes,
diabetes and hypertension, among other chronic conditions.
The Initiative is a partnership between the UK Israel Tech Hub,
which aims to help British companies partner with cutting-edge
technology companies in Israel;
DigitalHealth.London, a collaborative that helps high-potential,
digital health start-up companies connect with the NHS; and Dangoor
Education.
DH.L is well placed to accelerate the adoption and scaling
of digital innovations across the NHS. The Initiative will help
facilitate additional access for DarioHealth to key UK clinicians,
academic institutes, healthcare system experts and industries in
order to better understand the needs of patients and the NHS.
"With 25 per cent of middle-aged adults suffering from
hypertension and 2.6 million people diagnosed with diabetes, the
NHS needs the very best in digital innovation in order to manage
chronic disease conditions successfully, now and into the future,"
said Dror Bacher, Chief Operating
Officer at DarioHealth Corp. "I recently had the pleasure of
meeting key NHS clinicians and influencers and learned first-hand
about the challenges and opportunities that they're experiencing
within the healthcare sector. DarioHealth is well positioned to
offer quality digital therapeutic interventions for managing
chronic conditions and looks forward to exploring opportunities for
integration and partnership with both primary and secondary care
providers. Through our collaboration, we will examine the best ways
to develop new Dario digital therapeutic solutions for people with
chronic conditions within the framework of the NHS."
A key differentiator of Dario's performance-based platform is
its emphasis on behavioral engagement with users, through the
offering of personalised interventions, which is a unique approach
in the digital therapeutics' arena. DarioHealth's platform focuses
on the user's needs, experience and satisfaction. We believe that
this approach disrupts the traditional approach used by most
healthcare companies and makes the Dario platform the most popular
product by people managing diabetes and pre-diabetes.
DarioHealth continues to find new, innovative ways to assist its
users in improving their health through ongoing analysis of
clinical-data studies and the application of new digital solutions.
By delivering personalized, evidence-based interventions driven by
precision data analytics, high-quality software and personalised
coaching, DarioHealth has a dynamic health management approach that
empowers individuals to make informed, data-driven choices that
improve their short and long-term health. Dario's membership
programs offer professional coaching to individuals with
pre-diabetes, diabetes and hypertension to provide them a clear and
timely view of their condition in a user-friendly format directly
on their iPhone or Android mobile device.
DarioHealth's most recently introduced digital product, the
Dario Blood Pressure Monitoring System™, assists hypertension
patients in managing their blood pressure throughout the day,
further solidifying the company's presence in the hypertension
management market.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital
therapeutics company revolutionising the way people with chronic
conditions manage their health. By delivering evidence-based
interventions that are driven by data, high-quality software and
coaching, we empower individuals to make healthy adjustments to
their daily lifestyle choices to improve their overall health. Our
cross-functional team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Dario is one of the
highest-rated diabetes solutions in the market, and its
user-centric Dario mobile app is loved by tens of thousands of
consumers around the globe. DarioHealth is rapidly moving into new
chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions via the Dario mobile app, please go
to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. "For example, when Dario states that it
will bring its highly regarded digital therapeutics technology to
assist NHS patients in better managing their chronic health
conditions, that the Initiative will help facilitate additional
access for DarioHealth to key UK clinicians, academic institutes,
healthcare system experts and industries in order to better
understand the needs of patients and the NHS, that Dario's approach
of emphasizing behavioral engagement with users disrupts the
traditional approach used by most healthcare companies and makes
the Dario platform the most popular product by people managing
diabetes and pre-diabetes, it is using forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialisation or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario)
may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1 347-767-4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1 917-330-8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-announces-alliance-with-digitalhealthlondon-as-part-of-the-uk-israel-dangoor-health-initiative-300902353.html
SOURCE DarioHealth Corp.